Germline mutations in BRCA1/2 predispose individuals to breast cancer (termed germline-
mutated BRCA1/2 breast cancer, gBRCA-BC) by impairing homologous recombination (HR) …

Triple-negative breast cancer (TNBC) is an aggressive disease with limited treatment
options and poor prognosis once metastatic. Pre-clinical and clinical data suggest that …

Triple-negative breast cancer (TNBC) is one of the most heterogeneous diseases in solid
tumors and has limited therapeutic options. Due to the lack of appropriate targetable …

Background Aberrant DNA methylation is frequently observed in breast cancer. However,
the relationship between methylation patterns and the heterogeneity of breast cancer has …

Abstract The Cancer/Testes (CT) Antigen HORMAD1 is germ cell-restricted and plays
developmental roles in generation and processing of meiotic DNA Double Strand Breaks …

HORMA domain‑containing protein 1 (HORMAD1), is normally expressed only in the
germline, but is frequently re‑activated in human triple‑negative breast cancer (TNBC); …

Triple-negative breast cancer (TNBC) is a highly aggressive breast cancer (BrC) subtype
lacking effective therapeutic targets currently. The development of multi-omics databases …

Triple negative breast cancers (TNBCs) lack recurrent targetable driver mutations but
demonstrate frequent copy number aberrations (CNAs). Here, we describe an integrative …

Chromosomal instability not only has a negative effect on survival in triple-negative breast
cancer, but also on the well treatable subgroup of luminal A tumors. This suggests a general …

The TP53 gene is the most commonly mutated gene in human cancers and mutations in
TP53 have been shown to have either gain-of-function or loss-of-function effects. Using the …